Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Intensity Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
INTS
Nasdaq
2830
www.intensitytherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Intensity Therapeutics, Inc.
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
- Jan 28th, 2025 1:00 pm
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
- Jan 10th, 2025 1:00 pm
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
- Dec 13th, 2024 1:10 pm
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
- Dec 12th, 2024 4:26 pm
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
- Dec 12th, 2024 1:00 pm
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
- Nov 21st, 2024 1:00 pm
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
- Nov 18th, 2024 1:00 pm
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 13th, 2024 9:06 pm
3 US Penny Stocks With Market Caps Under $200M To Watch
- Nov 13th, 2024 8:07 pm
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
- Nov 8th, 2024 1:01 pm
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
- Oct 31st, 2024 1:00 pm
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 4th, 2024 12:00 pm
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 8th, 2024 8:19 pm
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
- Jul 9th, 2024 12:01 pm
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
- Jun 6th, 2024 11:26 am
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
- May 15th, 2024 12:01 pm
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
- May 10th, 2024 12:01 pm
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- May 9th, 2024 8:08 pm
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
- Apr 2nd, 2024 12:01 pm
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
- Mar 26th, 2024 12:01 pm
Scroll